CORPORATE ACCESS

A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.

Your Search ChromaDex News

Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients

Nov 15, 2023 | ,

This is the longest Niagen NR clinical trial to date spanning two years and showcases that long-term Niagen NR is safe and well tolerated LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), one of the global authorities on Nicotinamide Adenine Dinucleotide (NAD+) and healthy...

read more

ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide

Nov 1, 2023 | ,

Tru Niagen® Pro 1,000mg is recommended by physicians and used by pro-athletes as it is clinically proven to boost NAD+ levels by up to 150% in as little as three weeks LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine...

read more

A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients

Oct 2, 2023 | ,

Celebrating a significant achievement in NAD+ research, these findings contribute to the mounting evidence indicating that NR may serve as a proactive safeguard against inflammatory cytokines in healthy adults and those with inflammation-related disorders LOS ANGELES...

read more

Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN

Aug 24, 2023 | ,

This study, which utilized the gold standard method of stable isotopes, reinforces that NMN cannot cross the cell membrane directly and must first be converted to NR LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide...

read more
Skip to content